Claims for Patent: 6,060,283

Summary for Patent: 6,060,283

Title:	Genomic DNA encoding human interleukin-18 (IL-18, interferon-.gamma. inducing factor)
Abstract:	Disclosed is a genomic DNA encoding a polypeptide capable of inducing the production of interferon-.gamma. by immunocompetent cells. The genomic DNA efficiently expresses the polypeptide with high biological activities of such as inducing the production of interferon-.gamma. by immunocompetent cells, enhancing killer cells\' cytotoxicity and inducing killer cells\' formation, when introduced into mammalian host cells. The high biological activities of the polypeptide facilitate its uses to treat and/or prevent malignant tumors, viral diseases, bacterial infectious diseases and immune diseases without serious side effects when administered to humans.
Inventor(s):	Okura; Takanori (Okayama, JP), Torigoe; Kakuji (Okayama, JP), Kurimoto; Masashi (Okayama, JP)
Assignee:	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo (Okayama, JP)
Application Number:	08/884,324
Patent Claims:	1. An isolated DNA molecule comprising a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO:1, where Xaa is isoleucine or threonine, wherein said nucleotide sequence consists of the sequence of a fragment of human genomic DNA. 2. An isolated DNA molecule according to claim 1, wherein said nucleotide sequence comprises an exon having the sequence shown in SEQ ID NO:3, 4, 5, 6, or 7. 3. An isolated DNA molecule according to claim 1, wherein said nucleotide sequence comprises an intron having the sequence shown in SEQ ID NO:8, 9, 10, 11, or 12. 4. The isolated DNA molecule according to claim 1, wherein said nucleotide sequence is the sequence shown in SEQ ID NO:13 or 14. 5. A process for preparing a polypeptide of SEQ ID NO:1, comprising the steps of: artificially expressing the polypeptide of SEQ ID NO:1, where Xaa represents isoleucine or threonine, from the isolated DNA molecule according to claim 1; and recovering the expressed polypeptide to prepare the polypeptide of SEQ ID NO:1. 6. An autonomously replicable vector into which the isolated DNA molecule according to claim 1 is inserted. 7. A mammalian host cell transformed with the isolated DNA molecule according to claim 1, wherein said transformed host cell is capable of expressing a polypeptide of SEQ ID NO:1, where Xaa represents isoleucine or threonine, in culture. 8. A transformed mammalian host cell according to claim 7, which is selected from the group consisting of an epithelial cell, an interstitial cell and a hemopoietic cell. 9. A process for preparing a polypeptide of SEQ ID NO:1, comprising the steps of: culturing the transformed mammalian host cell of claim 7 in a nutrient culture medium to express the polypeptide of SEQ ID NO:1, where Xaa represents isoleucine or threonine; and recovering the expressed polypeptide from the culture medium to prepare the polypeptide of SEQ ID NO:1. 10. The process according to claim 9, wherein the polypeptide of SEQ ID NO:1 is recovered by immunoaffinity chromatography with a monoclonal antibody against the polypeptide of SEQ ID NO:1. 11. The process according to claim 9, wherein the polypeptide is recovered by one or more purification techniques selected from the group consisting of salting out, dialysis, filtration, concentrating a solution, separatory sedimentation, ion-exchange chromatography, gel filtration chromatography, adsorption chromatography, isoelectric point chromatography, hydrophobic chromatography, reversed phase chromatography, affinity chromatography, gel electrophoresis, and isolectric focusing. 12. An isolated subgenomic DNA molecule comprising the nucleotide sequence shown in SEQ ID NO:8, 9, 10, 11, or 12.

Details for Patent 6,060,283

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2016-06-27
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2016-06-27
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2016-06-27